Back to search

National and Kapodistrian University of Athens

Μελέτη μεταβλητών για τη μετεγχειρητική παρακολούθηση, πρόγνωση, σχεδιασμό και ανταπόκριση στη θεραπευτική αγωγή ασθενών με μελάνωμα

Abstract

dc:description

Research aimS100 protein is the best studied and widely accepted tumor marker for melanoma. The importance or S100B as a tumor marker for malignant melanoma is focused that it can be used to serve several purposes and mainly to appreciate the extent of the disease, to evaluate the treatment response, prognosis, to detect metastasis and follow up. The main purpose of this study was to assess the biological ‘behavior’ of the variables S100B (mainly) and LDH, so that they can be used as tumor markers for melanoma and to investigate potential correlations of S100B protein with characteristics and features of primary melanoma.Patents and MethodsFrom 2012 to 2015, 107 melanoma patients (54 males and 53 females) were diagnosed with excisional biopsy included in this study. The patients underwent wide local excision and sentinel lymph node biopsy (SLNB). SLNB positive patients underwent lymph node dissection of the corresponding lymph node basin. 39 patients were in stage I, 33 in stage II, 26 in stage III, and 9 in stage IV. With regards the staged III patients, 11 were N1, 6 were N2, and 9 were N3. 5 patients were diagnosed with multiple primary melanomas. The NCCN high risk features for melanoma such as ulceration, lymphovascular invasion and ulceration, were documented. Patients’ survival for each stage was documented. Serial measurements of serum S100B concentrations and LDH were performed perioperatively and during follow up. Statistical analysis was performed to evaluate the S100B levels for each stage and its correlations with the above characteristics, as well as to assess the reliability of S100B protein as a melanoma tumor marker for the treatment response, follow up, prognosis and survival. Potential correlation of S100B with LDH was also investigated.ResultsMelanoma patients in stage I and II had usually normal levels of serum S100B concentrations. Staged III patients had usually increased S100B values above the upper normal limit. Staged IV patients had very high S100B values above the upper normal limit (0.11μg/l), and well above the previous other stages. Patients who were previously in stage III and had increased S100B values, are at increased risk to progress in stage IV. With disease progression to stage IV the above patients developed significant higher S100B values. S100B levels are correlated with the lymph node status of staged III patients. In our study S100B values were significant higher in stages N3 and N2 compared to N1, whereas no statistical significant difference was documented among N3 and N2 patients. With regards the correlation of S100B protein with the NCCN high risk features, there was positive correlation of S100B with the number of mitoses, and it was strong only for stage IV. In patients with multiple melanomas, S100B values are not ‘cumulative’, but are based and reflect the stage of the disease, which is determined by the melanoma with the most advanced stage. Overall survival was significant lower for patients in stage IV compared to the other stages, whereas S100B >0.5 μg/l serum values, almost fivefold above the upper normal limit, were correlated with stage IV, low survival, and increased death rate. LDH is important for patients in stage IV, but there is no statistical significant correlation between the two variables S100B and LDH.ConclusionsS100B protein concentrations in the peripheral blood reflect the tumour load and the disease, are considered as reliable tumour marker for the treatment response, follow up, prognosis, presence of metastasis and survival, and therefore they should be included in the laboratory blood tests of melanoma patients during follow up. Increased S100B values are correlated with worse prognosis and low survival. S100B levels are correlated with the disease stage and are very high in stage IV. Patients in stage III with increased S100B values are at increased risk to progress in stage IV. For this group of patients the oncologists should re-design or modify their complementary treatment. The S100B is a prognostic marker independent to LDH for all melanoma stages.The measurement of S100B serum concentrations is considered a powerful, useful and reliable tool that offers significant findings for the assessment and management of melanoma patients. The S100B measurement is a simple and safe test with low cost and when is used with other diagnostic modalities, it increases the diagnostic accuracy and serves the better management of melanoma patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karonidis, Athanasios
  • Καρονίδης, Αθανάσιος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41145

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karonidis, Athanasios; Καρονίδης, Αθανάσιος. Μελέτη μεταβλητών για τη μετεγχειρητική παρακολούθηση, πρόγνωση, σχεδιασμό και ανταπόκριση στη θεραπευτική αγωγή ασθενών με μελάνωμα. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/41145